Printer Friendly

Sibutramine metaanalysis.

Sibutramine use was significantly associated with weight loss and appears to improve glycemic control and lipid profile in type 2 diabetics, reported Roberto Vettor, M.D., of the University of Padova, Italy, and his colleagues.

In a metaanalysis of eight placebo-controlled, double-blind trials, 552 obese patients with type 2 diabetes were randomized to sibutramine treatment, and 541 were randomized to placebo. Body weight decreased by a mean of 5.5 kg in sibutramine users and by 0.9 kg in placebo users. Waist circumference decreased a mean of 5.3 cm in treated patients and by 1.1 cm with placebo (Diabetes Care 2005;28:942-9).

Mean changes in basal blood glucose were small, but the difference between the two groups was statistically significant, the investigators said. Treatment benefits also were seen in the levels of glycated hemoglobin (Hb[A.sub.1c]), serum triglycerides, and HDL cholesterol.
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:CLINICAL CAPSULES
Author:Foley, Kevin
Publication:Internal Medicine News
Article Type:Brief Article
Geographic Code:1USA
Date:Jul 1, 2005
Words:147
Previous Article:Predicting metabolic syndrome.
Next Article:BMI tied to meniscal tears.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters